Kalvebod Brygge 43
45 70 20 27 28
Full-time employees: 1,660
|Dr. Jan G.J. van de Winkel Ph.D.||Co-Founder, Pres & CEO||18.8M||N/A||1961|
|Mr. Anthony Pagano||Exec. VP & CFO||7M||N/A||1978|
|Mr. Anthony Mancini||Exec. VP & COO||7.6M||N/A||1971|
|Mr. Martin Schultz||Sr. Director of Clinical Operations & Non-Independent Director||500k||N/A||1976|
|Dr. Judith V. Klimovsky M.D.||Exec. VP & Chief Devel. Officer||7.9M||N/A||1958|
|Dr. Tahamtan Ahmadi||Exec. VP, Chief Medical Officer & Head of Experimental Medicines||7.5M||N/A||1973|
|Dr. Mijke Zachariasse Ph.D.||Sr. Director, Head of Antibody Research Materials & Non-Independent Director||1M||N/A||1974|
|Mr. Takahiro Hamatani||Sr. Director of Fin. Japan & Non-Independent Director||500k||N/A||1975|
|Mr. Andrew Carlsen||Sr. Director, VP & Head of Investor Relations||N/A||N/A||N/A|
|Ms. Birgitte Stephensen M.Sc.||Exec. VP & Chief Legal Officer||N/A||N/A||1961|
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Genmab A/S’s ISS governance QualityScore as of 1 March 2023 is 1. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 1; Compensation: 1.